This NDC is on FDA's drug shortage list (posted Jul 26, 2023)
Reported reason: Other
Product Information
METHYLPHENIDATE ER 36 MG TAB is a generic product labeled by Actavis Pharma, Inc., priced at $0.6715 per EA under NDC 62037072601. Its NADAC has been published 388 times since May 1, 2019.
FDA first approved this application on Mar 22, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
36 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
62037072601
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA076772FDA Approved
3/22/2018
TE Code
AB
On Market Since
3/4/2019
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE ER 36 MG TAB has been published 388 times since May 1, 2019, and over the history we have for it it has declined 90.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6715 per EA |
|---|---|
| All-time high | $7.0589 (May 15, 2019) |
| All-time low | $0.6033 (Apr 17, 2024) |
| 52-week high | $0.7504 |
| 52-week low | $0.6632 |
| Median price | $0.9593 |
| Average price | $1.5450 |
| Largest weekly change | -36.0% (Sep 23, 2020) |
| Weeks tracked | 388 |
| Tracking since | May 1, 2019 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE ER 36 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE ER 36 MG TAB, manufactured by Actavis Pharma, Inc., is $0.6715 per EA (NDC 62037072601), effective Sep 30, 2026.
How has the price of METHYLPHENIDATE ER 36 MG TAB changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE ER 36 MG TAB has declined 90.5%. It has been tracked across 388 weekly CMS publications since May 1, 2019.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE ER 36 MG TAB?
Since May 1, 2019, the NADAC for METHYLPHENIDATE ER 36 MG TAB has ranged from a low of $0.6033 (Apr 17, 2024) to a high of $7.0589 (May 15, 2019), with a median of $0.9593 per EA.
Are there cheaper alternatives to METHYLPHENIDATE ER 36 MG TAB?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPHENIDATE ER 36 MG TAB, is $0.6665 per EA — about 1% below METHYLPHENIDATE ER 36 MG TAB.
Who manufactures METHYLPHENIDATE ER 36 MG TAB?
METHYLPHENIDATE ER 36 MG TAB (NDC 62037072601) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.
Is METHYLPHENIDATE ER 36 MG TAB in shortage?
Yes — NDC 62037072601 is currently listed in FDA's drug shortage database (posted Jul 26, 2023). Reported reason: Other.